Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients

American Journal of Kidney Diseases

Volumn 57, Issue 6, 2011, Pages 963-965

  Ix, Joachim H ^a   Ganjoo, Prerna ^b   Tipping, Diane ^c   Tershakovec, Andrew M ^c   Bostom, Andrew G ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; CALCIUM ACETATE; CREATININE; LANTHANUM CARBONATE; LAROPIPRANT PLUS NICOTINIC ACID; PHOSPHORUS; PLACEBO; SEVELAMER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; HYPERPHOSPHATASEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LETTER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PHOTOMETRY;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; HYPOPHOSPHATEMIA; INDOLES; KIDNEY FAILURE, CHRONIC; LIPIDS; NIACIN; TREATMENT OUTCOME;

EID: 79956358444     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.03.010     Document Type: Letter

References (10)

1. G.A. Block, M.S. Persky, and M. Ketteler A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology Hemodial Int 13 2009 360 362
2. T. Isakova, O.M. Gutierrez, and M. Wolf A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease Kidney Int 76 2009 705 711
3. A.G. Bostom Binder blindersniacin of omission? Am J Kidney Dis 55 4 2010 628 630
4. S. Hu, G.C. Shearer, M.W. Steffes, W.S. Harris, and A.G. Bostom Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia Am J Kidney Dis 57 1 2011 181 182
5. D. Maccubbin, D. Tipping, O. Kuznetsova, W.A. Hanlon, and A.G. Bostom Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial Clin J Am Soc Nephrol 5 4 2010 582 589
6. A.G. Bostom, A. MacLean, D. Maccubbin, D. Tipping, H. Gizek, and W. Hanlon Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia [abstract] J Clin Lipidol 4 2010 198 199
7. A.S. Levey, L.A. Stevens, C.H. Schmid CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
8. L.A. Carlson Nicotinic acid: the broad-spectrum lipid drug A 50th anniversary review J Intern Med 258 2 2005 94 114 (Pubitemid 41025967)
9. R.B. Oliveira, A.L. Cancela, and F.G. Graciolli Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKDMBD therapy? Clin J Am Soc Nephrol 5 2 2010 286 291
10. Isakova T, Gutirrez OM, Smith K, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease [published online ahead of print July 14, 2010]. Nephrol Dial Transplant. doi:10.1093/ndt/gfq419.